Abstract
To the Editor: The incidence and severity of COVID-19 among patients with autoimmune bullous skin diseases (AIBD) have not been characterized in large populations.1-3 We assessed the severity and mortality of COVID-19 in patients with AIBD, with a special interest in a potential risk factor related to previous treatment with rituximab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
